ACT-20-MSC
/ Secretome Therapeutics, Aspire Health Science
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 21, 2020
ACT-20 in Patients With Severe COVID-19 Pneumonia
(clinicaltrials.gov)
- P1/2; N=70; Not yet recruiting; Sponsor: Aspire Health Science
Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases
1 to 1
Of
1
Go to page
1